Human Genome Sciences Announces Proposed Public Offering of Co...(tion of an offer to buy any securities o...)

Date:7/27/2009

tion of an offer to buy any securities of Human Genome Sciences, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. The offering will be made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., at 85 Broad Street, New York, New York 10004, Attention: Prospectus Department, Toll-Free 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com and Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58(th) Street, 8(th) Floor, Brooklyn, NY 11220, Attention: Prospectus Department, 800-831-9146.

About Human Genome Sciences

Human Genome Sciences is a commercially focused biopharmaceutical company. In the first half of 2009, HGS achieved its first product revenues of $162.7 million when we delivered raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for the treatment of inhalation anthrax. HGS has two other products in late-stage clinical development: ZALBIN(TM) (formerly Albuferon((R))) for chronic hepatitis C and BENLYSTA((TM)) (formerly LymphoStat-B((R))) for systemic lupus erythematosus.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472.

HGS, Human Genome Sciences, ABthrax, Albuferon, BENLYSTA, and ZALBIN are trademarks of Human Genome Sciences, Inc.

'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. OMT announces a breakthrough in the development of a novel human antibody platform
2. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
3. Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
4. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
5. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
6. Fruit fly steps in to fight human disease
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
8. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
9. Assessment of safety and efficacy of human embryonic stem cell therapy
10. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
11. Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue